OR WAIT null SECS
The BalanCD CHO media portfolio is designed to ensure maximized growth, viability, and productivity of CHO cell lines.
FUJIFILM Irvine Scientific, Inc. announced its growth of the BalanCD Chinese Hamster Ovary (CHO) Media Platform portfolio with the addition of two new, chemically defined growth media- BalanCD CHO Perfusion and BalanCD CHO DG44.
The BalanCD CHO media portfolio is designed to ensure maximized growth, viability, and productivity of CHO cell lines via a scalable platform for reliable production and seamless workflow through all stages of development and manufacture, including small-scale shake flasks to large bioreactors. The new additions increase the platform with specific media designed to support DG44 cell lines and perfusion culture platforms for the commercialization of monoclonal antibodies, recombinant proteins, biosimilars, and other biomolecule-based biotherapeutics.
According to the press release, the BalanCD CHO Perfusion medium is a chemically defined, animal component-free medium optimized to deliver robust cell growth and productivity in steady-state, perfusion CHO culture. This medium is verified to meet industry performance standards for perfusion culture conditions including volumetric productivity (VP), cell specific perfusion rates (CSPR), and vessel volumes per day (VVD).
Additionally, BalanCD CHO Perfusion is a complete, ready-to-use medium that is adaptable and scalable for a variety of perfusion culture platforms, including perfusion mimic and perfusion-capable bioreactors. It is designed for high cell density conditions and to deliver high titers, and BalanCD CHO DG44 medium is specifically created for optimal growth and productivity of CHO DG44 cell lines. It also supports both batch and fed-batch cultures, which makes it highly compatible with a wide range of culture platforms and transfection reagents.
“With CHO cells being such a pivotal part of many biotherapeutic development and manufacture pipelines, FUJIFILM Irvine Scientific designed the BalanCD CHO platform to deliver consistent, high-quality growth of CHO cells and production of biomolecules to accelerate the development and manufacture of life-saving therapies for patients around the world and achieve more cost-efficiencies within biotherapeutic manufacturing,” said Erik Vaessen, chief business officer, FUJIFILM Irvine Scientific, in a press release.